Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form

G. B. Kolyvanov; V. P. Zherdev; O. G. Gribakina; P. O. Bochkov; R. V. Shevchenko; A. A. Litvin; E. V. Blynskaya; V. V. Bueva

doi:10.1007/s10517-019-04587-w

Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form

Autores: Kolyvanov G.¹, Zherdev V.¹, Gribakina O.¹, Bochkov P.¹, Shevchenko R.¹, Litvin A.¹, Blynskaya E.², Bueva V.²
Afiliações:
1. Laboratory of Pharmacokinetics
2. Laboratory of Finished Dosage Forms, V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences
Edição: Volume 167, Nº 5 (2019)
Páginas: 637-640
Seção: Article
URL: https://journals.rcsi.science/0007-4888/article/view/241978
DOI: https://doi.org/10.1007/s10517-019-04587-w
ID: 241978

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Estatísticas

Resumo

Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.